SCHEMBL59462

SCHEMBL59462

O=C(Cl)Oc1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.48
LIPE Q05469 4/20 0.47
HPGD P15428 1/20 0.47
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
PPARA Q07869 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
HTT P42858 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
BCHE P06276 1/20 0.43
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5665614 0.93 ELANE (0.44) ELANELIPEHPGDCYP11B1CYP11B2
SCHEMBL8028437 0.91 TAAR1 (0.50) ELANEMEN1KMT2AMAPTCYP1A2
SCHEMBL6924446 0.89 RAB9A (0.46) ELANEMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL6565732 0.82 HSD17B10 (0.47) ELANEMEN1KMT2AMAPTCYP1A2
SCHEMBL56865 0.82 KMT2A (0.50) ELANELIPEHPGDCYP11B1CYP11B2
SCHEMBL6564201 0.82 ELANE (0.52) ELANEHPGDMEN1KMT2AMAPT
SCHEMBL7063178 0.82 ELANE (0.50) ELANELIPEHPGDCYP11B1CYP11B2
SCHEMBL8465167 0.81 LIPE (0.49) ELANELIPEHPGDCYP11B1CYP11B2
SCHEMBL9578961 0.80 MAPT (0.50) ELANEHPGDMEN1KMT2AMAPT
SCHEMBL1254449 0.80 ELANE (0.48) ELANELIPEHPGDCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 953 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116496445-B Star polymer, preparation method and application thereof, dispersing agent and dispersing method 中国科学院宁波材料技术与工程研究所 2025-05-30 CN claimed
CN-116496445-A Star polymer, preparation method and application thereof, dispersing agent and dispersing method 中国科学院宁波材料技术与工程研究所 2023-07-28 CN claimed
CN-116444742-A Polymer based on phenol group modified aliphatic structure, preparation method thereof and dispersing agent 中国科学院宁波材料技术与工程研究所 2023-07-18 CN claimed
CN-116332809-A Process for producing alkylamine derivative and intermediate for production thereof 味之素株式会社 2023-06-27 CN claimed
CN-115536556-A Process for producing alkylamine derivative and intermediate for producing the same 味之素株式会社 2022-12-30 CN claimed
CN-109689848-A Spice composition 奇华顿股份有限公司 2019-04-26 CN claimed
EP-3305760-A1 METHOD FOR PRODUCING ALKYLAMINE DERIVATIVE AND PRODUCTION INTERMEDIATE OF ALKYLAMINE DERIVATIVE AJINOMOTO CO., INC. (JP) 2018-04-11 EP claimed
US-20180079715-A1 METHOD FOR PRODUCING ALKYLAMINE DERIVATIVE AND ITS PRODUCTION INTERMEDIATE OF ALKYLAMINE DERIVATIVE AJINOMOTO CO., INC. (JP) 2018-03-22 US claimed
US-20170298029-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2017-10-19 US claimed
CN-107073153-A The product of material is reduced comprising stench 宝洁公司 2017-08-18 CN claimed
EP-2125754-A1 AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM Aurobindo Pharma Limited (IN) 2009-12-02 EP claimed
WO-2008096257-A1 AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM AUROBINDO PHARMA LIMITED (IN) 2008-08-14 WO claimed
US-20080153836-A1 N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders NOVARTIS AG (CH) 2008-06-26 US claimed
EP-1871749-A1 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS Novartis AG (US) 2008-01-02 EP claimed
WO-2006108591-A1 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS NOVARTIS AG (CH) 2006-10-19 WO claimed
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2006-05-18 US claimed
JP-2005534635-A 2005-11-17 JP claimed
EP-1506176-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-02-16 EP claimed
WO-2003097610-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2003-11-27 WO claimed
US-6015656-A TABULAR SILICA DISPERSION OBTAINED BY MIXING TABULAR SILICA, GELATIN, CYCLODEXTRIN, COMPOUND CAPABLE OF CROSSLINKING GELATIN KONICA CORPORATION (JP) 2000-01-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K15, MAP3K3, MAP3K20 ELANE 3929/4885LIPE 3391/4885HPGD 3158/4885
US-20170298029-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF ELANE 3035/4885LIPE 3001/4885HPGD 2930/4885
US-20180079715-A1 METHOD FOR PRODUCING ALKYLAMINE DERIVATIVE AND ITS PRODUCTION INTERMEDIATE OF ALKYLAMINE DERIVATIVE CASR, TAAR1, UTS2R ELANE 3914/4885LIPE 2871/4885HPGD 2454/4885
US-20080153836-A1 N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders GRIN2A, GRIN1, GRIN2D ELANE 4842/4885LIPE 4744/4885HPGD 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.